ARA-290 Vial Size — Dosing and Storage Essentials

Most researchers assume ARA-290 vial size is standardized across suppliers—it's not. Vials range from 2mg to 10mg of lyophilized powder, and choosing the wrong concentration can compromise dosing precision, storage duration, and ultimately, your experimental outcomes. The difference between a 2mg vial and a 10mg vial isn't just quantity—it's reconstitution volume, dose calculation complexity, and how long your peptide remains stable once mixed.

We've guided hundreds of research teams through peptide procurement and reconstitution protocols. The gap between doing it right and doing it wrong comes down to three things most suppliers never mention upfront: vial concentration matching your experimental design, bacteriostatic water volume ratios, and post-reconstitution stability windows.

What is the standard ARA-290 vial size for research applications?

ARA-290 vial size commonly ranges from 2mg to 10mg of lyophilized powder per vial, with 5mg being the most frequently supplied concentration. The 'size' refers to the total peptide mass contained in the vial before reconstitution—not the physical vial dimensions. Selecting the appropriate ara-290 vial size depends on your dosing frequency, experimental timeline, and whether multiple subjects or trials will use the same reconstituted solution. Smaller 2mg vials suit short-term studies with infrequent dosing, while 10mg vials are cost-effective for extended protocols requiring daily administration.

The ara-290 vial size you choose directly impacts your reconstitution calculations. A common misconception is that larger vials always offer better value—but if your protocol uses 200mcg doses twice weekly, a 10mg vial reconstituted at standard concentration will remain open for six weeks, pushing the stability envelope beyond what bacteriostatic water can reliably preserve. This article covers how to match ara-290 vial size to your experimental parameters, calculate precise reconstitution volumes for any concentration, and store peptides to maintain structural integrity across your research timeline.

Understanding ARA-290 Peptide Concentrations and Vial Formats

ARA-290 is supplied as a lyophilized (freeze-dried) powder in hermetically sealed vials, typically containing 2mg, 5mg, or 10mg of the active peptide. The peptide itself is a synthetic analogue of erythropoietin (EPO) designed to bind tissue-protective receptors without stimulating red blood cell production—a mechanism that makes it valuable in neuroprotection and inflammation research. Unlike recombinant proteins that require cold-chain shipping from the manufacturer, lyophilized ARA-290 remains stable at room temperature for short durations, though long-term storage at −20°C is standard protocol.

The ara-290 vial size designation refers exclusively to peptide mass, not the physical vial capacity. A 5mg vial of ARA-290 contains 5mg of peptide plus excipients (typically mannitol or trehalose as stabilizers), but the vial itself holds 3–5mL of liquid once reconstituted. This distinction matters because reconstitution volume determines final concentration—add 2mL of bacteriostatic water to a 5mg vial and you create a 2.5mg/mL solution; add 5mL and you create a 1mg/mL solution. Researchers often assume the vial size dictates reconstitution volume, but it's the reverse: your desired working concentration should determine how much diluent you add.

Vial format also influences contamination risk. Multi-dose vials, which most peptide suppliers use, are designed for repeated needle punctures through a rubber stopper. Bacteriostatic water—sterile water containing 0.9% benzyl alcohol as a preservative—inhibits bacterial growth for up to 28 days post-reconstitution, but only if sterile technique is maintained. Each puncture slightly degrades the stopper integrity, which is why protocols using 10mg vials over extended periods carry higher contamination risk than those using multiple 2mg vials sequentially. At Real Peptides, every ARA-290 vial undergoes USP sterility testing and is sealed under nitrogen atmosphere to minimize oxidation before reconstitution.

Reconstitution Math: Matching Vial Size to Protocol Dosing

Dosing precision depends on matching ara-290 vial size to your experimental design before you order. The most common research protocols use ARA-290 at 1–4mg per dose administered subcutaneously, typically 2–3 times per week. If your protocol requires 2mg doses and you're using a 10mg vial, that's five doses per vial—but if each subject receives two doses weekly, that vial must remain stable for 2.5 weeks post-reconstitution. Bacteriostatic water extends stability to 28 days refrigerated, but peptide degradation accelerates with each temperature fluctuation during storage and withdrawal.

Here's the calculation framework: decide your per-dose volume before reconstituting. Most researchers target 0.2–0.5mL per injection for subcutaneous administration—larger volumes cause injection site discomfort and slower absorption. If you want each 2mg dose delivered in 0.4mL, your target concentration is 5mg/mL (2mg ÷ 0.4mL). To achieve 5mg/mL from a 10mg vial, add 2mL of bacteriostatic water. From a 5mg vial, add 1mL. From a 2mg vial, add 0.4mL—though volumes below 1mL increase measurement error with standard insulin syringes.

The mistake most labs make is reconstituting all vials identically regardless of peptide mass. If you add 2mL to every vial 'by default,' a 2mg vial yields 1mg/mL while a 10mg vial yields 5mg/mL—your per-dose withdrawal volume then varies fivefold between vials, multiplying dosing errors. Standardize your final concentration across all vials instead. Our team has reviewed this across hundreds of peptide protocols—the pattern is consistent every time: labs that calculate backward from desired dose and injection volume experience fewer dosing discrepancies than those that calculate forward from arbitrary reconstitution volumes.

Stability Considerations: How Vial Size Affects Peptide Longevity

ARA-290 demonstrates excellent stability as a lyophilized powder—independent third-party analysis confirms less than 2% degradation after 24 months at −20°C and less than 5% degradation after six months at room temperature in sealed vials. Once reconstituted, stability drops dramatically. Dissolved peptides are vulnerable to hydrolysis, oxidation, and bacterial contamination—all of which accelerate at temperatures above 4°C. Bacteriostatic water mitigates bacterial growth but does nothing to prevent chemical degradation, which proceeds through cleavage of peptide bonds at predictable sites in the amino acid sequence.

The ara-290 vial size you select directly influences how long reconstituted peptide remains viable. A 2mg vial reconstituted for a one-week protocol can be used fresh and discarded, minimizing exposure to degradation pathways. A 10mg vial supporting a six-week protocol, however, requires 12–18 withdrawals through the stopper, each introducing micro-contamination risk and brief temperature excursions when removed from refrigeration. Studies on similar peptide structures—particularly those containing methionine and cysteine residues prone to oxidation—show 10–15% potency loss after 21 days in solution even under ideal refrigeration.

The practical ceiling for reconstituted peptide use is 28 days, but that's a bacteriostatic limit, not a potency guarantee. Peptide degradation is a gradient, not a binary threshold. After 14 days, you might retain 95% potency; after 28 days, perhaps 85–90%. If your protocol demands high precision—dose-response curves, receptor binding assays, or tightly controlled animal studies—splitting a large vial into smaller aliquots immediately after reconstitution and freezing unused portions at −80°C preserves potency better than keeping one multi-dose vial refrigerated for weeks. Freeze-thaw cycles do damage peptides, but a single freeze (within two hours of reconstitution) followed by a single thaw causes less degradation than 28 days of refrigerated storage with repeated withdrawals.

Storage Protocol: Temperature, Light, and Contamination Control

Unreconstituted ARA-290 should be stored at −20°C in the original sealed vial, protected from light and moisture. Lyophilized peptides are hygroscopic—they absorb atmospheric moisture rapidly if the seal is compromised, which can trigger partial reconstitution inside the vial and subsequent degradation even before you add bacteriostatic water. If you're purchasing multiple vials for a long-term study, verify each vial arrives with an intact crimp seal and store them in a desiccated environment if your freezer cycles above −15°C.

Once reconstituted, ARA-290 must be refrigerated at 2–8°C immediately. The window between reconstitution and refrigeration should not exceed 30 minutes—peptide degradation begins the moment the powder dissolves. Store reconstituted vials upright in the coldest section of the refrigerator (usually the back of the bottom shelf), away from the door to minimize temperature fluctuations during daily access. Wrap the vial in aluminum foil or store in an opaque secondary container to block light exposure, which catalyzes oxidation of aromatic amino acids.

Contamination control starts with sterile technique during reconstitution. Swab the vial stopper with 70% isopropyl alcohol and allow it to air-dry for 15 seconds before needle insertion. Use a fresh alcohol swab before every subsequent withdrawal—residual alcohol on the stopper can denature peptides at the injection site inside the vial. Never inject air into the vial to equalize pressure unless you've filtered that air through a 0.22-micron syringe filter—unfiltered air introduces particulates and potential contaminants. The pressure differential created by withdrawing solution without injecting air does pull atmospheric contaminants backward through the needle tract, so inject a small volume of bacteriostatic water (0.1–0.2mL) before withdrawing your dose to create positive pressure inside the vial.

ARA-290 Vial Size: Concentration Comparison

The table below compares standard ara-290 vial sizes, recommended reconstitution volumes, resulting concentrations, and practical use considerations for each format.

What If: ARA-290 Vial Size Scenarios

What If I Reconstitute a 10mg Vial But Only Need 2mg for My Experiment?

Divide the reconstituted solution into sterile cryovials immediately—within two hours of mixing—and freeze unused aliquots at −80°C. Reconstitute the 10mg vial with 4mL of bacteriostatic water to yield 2.5mg/mL, withdraw 0.8mL (2mg) into your working vial for immediate use, and aliquot the remaining 3.2mL into four separate 0.8mL portions. Each frozen aliquot can be thawed once for future use without significant potency loss. A single freeze-thaw cycle causes approximately 5–8% degradation, far less than the 15–20% degradation that occurs when a multi-dose vial sits refrigerated for 28 days with repeated access.

What If My Vial Arrives at Room Temperature—Is It Ruined?

Not necessarily, but it depends on duration and whether the vial was reconstituted. Lyophilized ARA-290 in sealed vials tolerates room temperature exposure for 48–72 hours with minimal degradation—peptides in solid form are far more stable than in solution. If the vial arrived sealed and shows no signs of moisture inside, refrigerate or freeze it immediately and use it as planned. If the package was in transit for more than five days at ambient temperature, request a replacement or accept a potential 5–10% potency reduction. Reconstituted vials, however, cannot tolerate temperature excursions above 8°C—if a mixed vial was left unrefrigerated for more than four hours, discard it.

What If I Accidentally Added Too Much Bacteriostatic Water—Can I Fix It?

You can't remove diluent, but you can recalculate your dosing volume. If you intended 2mL but added 4mL to a 5mg vial, your concentration dropped from 2.5mg/mL to 1.25mg/mL—you'll simply need to withdraw double the volume for each dose. The downside is larger injection volumes, which increase discomfort and slow absorption for subcutaneous administration. Volumes above 1mL per injection site often cause transient swelling and are better split into two separate injection sites. If the error produced a concentration too dilute for practical use (requiring 2–3mL injections), the only solution is to order a replacement vial and treat the diluted batch as a learning experience.

The Practical Truth About ARA-290 Vial Size Selection

Here's the honest answer: most researchers over-order vial size because they're optimizing for cost per milligram instead of experimental success. A 10mg vial costs 40–50% less per mg than a 2mg vial, but if your protocol uses 2mg weekly for three weeks, that 10mg vial forces you to maintain sterile multi-dose access for 21 days and accept 10–15% potency degradation by the final dose. The cost savings disappear the moment you need to repeat experiments due to inconsistent dosing.

The right ara-290 vial size isn't the one with the lowest unit price—it's the one that matches your experimental timeline and minimizes post-reconstitution storage duration. For pilot studies, single-subject trials, or any protocol where dose precision is critical to data interpretation, smaller vials deliver better results even at higher per-mg cost. For large cohorts or extended studies, larger vials make sense only if you have the lab infrastructure to aliquot and freeze unused portions immediately or if your protocol genuinely uses the entire vial within 14 days.

The peptide research community has a bias toward bulk purchasing that makes sense for highly stable compounds but backfires with peptides that degrade in solution. ARA-290 is not a small molecule—it's a 17-amino-acid peptide with multiple degradation pathways. Treat it like the precision tool it is. Match your ara-290 vial size to your timeline, calculate reconstitution volumes before you order, and store everything at the coldest temperature your protocol allows. The data quality improvement from fresh peptide consistently outweighs the cost savings from buying in bulk.

Peptide quality starts with supplier precision—explore high-purity research-grade compounds across our full peptide collection to find the formulation and vial size that matches your experimental needs.

The ara-290 vial size you choose shapes every aspect of your dosing protocol—from reconstitution calculations to storage logistics to final data reliability. Small vials suit precision work; large vials suit extended studies with proper aliquoting. There's no universal 'best' size—only the size that aligns with your specific experimental parameters and lab capabilities.